Cymbalta Fibromyalgia sNDA Could Make Lilly Product Lyrica’s First Competitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients treated with Cymbalta show greater reduction in pain compared to placebo in a six-month pivotal trial, Lilly reports.
You may also be interested in...
Lilly Wins Fibromyalgia Management Indication For Cymbalta
The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.
Lilly Wins Fibromyalgia Management Indication For Cymbalta
The blockbuster SNRI is second into the fibromyalgia space, following Pfizer’s Lyrica.
Lilly Submits Cymbalta For Chronic Pain
If approved for fibromyalgia and chronic pain, drug label would include six indications.